Ashariati Ami, Ugroseno S
Department Internal Medicine, Faculty of Medicine, Airlangga University-Dr. Soetomo Hospital, Surabaya, Indonesia.
Acta Med Indones. 2013 Apr;45(2):107-13.
to elucidate the pattern of molecular response assessed by logarithmic reduction in BCR-ABL transcription levels based on Sokal prognostic score in chronic phase chronic myeloid leukemia (CML) patients receiving Imatinib treatment.
cross-sectional study was conducted in the Hematologic Outpatient Clinic, Dr. Soetomo Hospital Surabaya in all chronic phase CML patients from June 2008 to June 2012. Data on subject characteristics (age and sex), complete blood count with differential and spleen size were collected. Patients were stratified according to Sokal score at diagnosis. Real-time quantitative PCR (RT-qPCR) were used to monitor BCR-ABL levels in patients who fulfilled study. Proportion difference of complete molecular response (MR) was analyzed by chi-square test, while differences of BCR-ABL transcript level among Sokal prognostic scole subgroups was analyzed by Kruskal-Wallis test.
40 subjects finished the study. After 18 months of Imatinib treatment, the undetected BCR-ABL transcript level (complete MR) were 7(70%), 8(66.7%), and 9(50%) in low-, intermediate-, and high risk group patients, respectively (p=0.417). Although proportion of subjects with complete MR is higher in sokal low risk group compared to in sokal high risk groups (70% v.s. 50%), but this difference is not statistically significant (p=0.557). Kruskal-Wallis test showed that there was no significant difference of BCR-ABL transcript level among Sokal prognostic score subgroup (p=0.734).
there was no difference of BCR-ABL transcript level among sokal prognostic score risk groups in chronic phase CML patients treated with Imatinib.
阐明在接受伊马替尼治疗的慢性期慢性髓性白血病（CML）患者中，基于索卡尔预后评分通过BCR-ABL转录水平对数降低评估的分子反应模式。
2008年6月至2012年6月期间，在泗水苏托莫博士医院血液科门诊对所有慢性期CML患者进行横断面研究。收集患者的特征数据（年龄和性别）、全血细胞计数及分类和脾脏大小。患者在诊断时根据索卡尔评分进行分层。对符合研究条件的患者使用实时定量聚合酶链反应（RT-qPCR）监测BCR-ABL水平。通过卡方检验分析完全分子反应（MR）的比例差异，而通过Kruskal-Wallis检验分析索卡尔预后评分亚组间BCR-ABL转录水平的差异。
40名受试者完成了研究。伊马替尼治疗18个月后，低、中、高风险组患者中未检测到BCR-ABL转录水平（完全MR）的分别有7例（70%）、8例（66.7%）和9例（50%）（p = 0.417）。虽然索卡尔低风险组中完全MR的受试者比例高于索卡尔高风险组（70%对50%），但这种差异无统计学意义（p = 0.557）。Kruskal-Wallis检验显示，索卡尔预后评分亚组间BCR-ABL转录水平无显著差异（p = 0.734）。
在接受伊马替尼治疗的慢性期CML患者中，索卡尔预后评分风险组间BCR-ABL转录水平无差异。
